Navigation Links
Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
Date:11/30/2007

ns in blood pressure than either drug alone. This, along with its favorable side-effect profile, should make AZOR an attractive treatment option for patients whose blood pressure does not respond to either component drug in isolation. U.S. approval was granted in September 2007.

While the reason for menopause remains unknown, KV Pharmaceutical believes EvaMist, which takes the third spot on the list, may offer significant advantages to women experiencing menopause. This product is a small, easy-to- use hand-held applicator that delivers a pre-set metered dose via the skin, releasing estradoil into the bloodstream over 24 hours. EvaMist gained FDA approval in July 2007.

The first of two potential treatments for cancer on the list of notable drugs gaining approval this quarter is Yondelis, developed by PharmaMar for patients who have not responded to previous regimens in their treatment of soft tissue sarcoma. Yondelis is the first approved product from PharmaMar, a Spanish biotech specializing in cancer drugs derived from marine organisms and has Orphan Drug status in both the EU and U.S., securing extended protection against generic competition.

The second approval win for Novartis this quarter, Tasigna, is an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia. Though the drug has been approved only in Switzerland for chronic myeloid leukemia, it is awaiting approval in the U.S. and Japan and has been recommended for approval across the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

* bevasiranib sodium, (Wet AMD), Opko

* recombinant active glucocerebrosidase, (Gaucher's disease), Protalix

* odanacatib, (osteoporosis), Merck & Co

* laquinimod, (multiple sclerosis), Active Biotech/Teva

* elesclomol, (solid tumors), Synta
'/>"/>

SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 29, 2014 AltMed , ... industry precision to the development and production of ... its primary location in Sarasota County. , ... a total commitment to attracting new industry and ... says David Wright, President and CEO of AltMed. ...
(Date:8/28/2014)... When David Gergen, President of Pro Player ... was asked to publicly support Mr. Brnovich in his ... seat in the State of Arizona, Mr. Gergen could ... Hall of Fame wide receiver Roy Green in addition ... Green, Kennard and Walczak are members of Pro Player ...
(Date:8/28/2014)... New Energy Works Timberframe plans for a ... country to Log & Timber Home Shows starting in ... Energy Works team will invite the shows’ attendees into ... expertise, project images, and their new 2015 project calendar. ... Mid-West Representative, will present “A fun-fill odyssey: Realizing your ...
(Date:8/28/2014)... 42-year-old investment banker arrives at the emergency department ... He drinks alcohol every dayoften at business lunches, ... health, he decided to quit drinking and had ... emergency. , It,s a common scenario in emergency ... alcohol consumption and develops withdrawal. , Withdrawal is ...
(Date:8/28/2014)... 28, 2014 On August 21, the ... its 2013 Annual Report, featuring the organization’s audited financial ... , According to the report, in 2013, the ... programs versus 14 cents on fundraising and administration. ... a minimum,” wrote the Foundation’s chief executive officer, Melinda ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... 2008) -- Pancreatic cancer is one of the ... in a major step forward, researchers at NewYork-Presbyterian ... radiation therapy prior to surgery nearly doubles survival ... "Patients who received pre-surgical (neoadjuvant) radiation had almost ...
... unmatched in its ability to deliver a ... across clinical settings to aid decision-making and ... announced that it earned two of Healthcare ... four of the five categories, ICA was ...
... Consumption and Kidney Cancer , There is no ... kidney cancer, according to a pooled analysis of prospective ... increasing worldwide, but the cause of the increase remains ... to an association between consumption of fat, protein, and ...
... , HARRISBURG, Pa., Nov. 25 In ... School District, the Pennsylvania Department of Health held vaccination clinics ... School on Nov. 19 and Nov. 24. , ... given to approximately 560 parents, students, and staff after an ...
... those with poor glucose control likely to have artery disease ... earlier research, a new study has identified a genetic ... in type 2 diabetes patients with poor sugar glucose (glycemic) ... on a genetic chromosome known as chromosome 9p21 are ...
... to blame, study concludes , , TUESDAY, Nov. 25 (HealthDay News) ... cancer for older women, according to a new study that ... their mammogram habits. , The weight itself is to blame ... who are above their healthy weight have higher levels of ...
Cached Medicine News:Health News:Radiation before surgery improves pancreatic cancer outcomes 2Health News:Radiation before surgery improves pancreatic cancer outcomes 3Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 2Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 3Health News:Also in the Nov. 25 JNCI 2Health News:Also in the Nov. 25 JNCI 3Health News:Also in the Nov. 25 JNCI 4Health News:Chromosome Linked to Diabetics' Heart Risks 2Health News:Weight Boosts Older Women's Breast Cancer Risk 2Health News:Weight Boosts Older Women's Breast Cancer Risk 3
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: